Quantcast
Last updated on April 20, 2014 at 17:20 EDT

Fuse Science Adds Renowned Duke University Team Physician to Board

June 29, 2011

AVENTURA, Fla., June 29, 2011 /PRNewswire/ — Double Eagle Holdings, Ltd. (OTCQB: DEGH), the parent company of Fuse Science, Inc. (www.fusescience.com), announced today that it has added Dr. David J. Berkoff to the company’s Board of Directors as its fifth and final voting member. Dr. Berkoff is a Duke University team physician and associate professor at Duke University’s Departments of Emergency Medicine and Sports Medicine. Dr. Berkoff will soon be leaving to join the Department of Orthopedics at the University of North Carolina-Chapel Hill School of Medicine. Fuse Science is a developer of novel, patent-pending technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals.

(Logo: http://photos.prnewswire.com/prnh/20110615/CL20255LOGO )

“Dr. Berkoff’s extensive experience and research with top athletes and endurance sports make him ideally suited to help guide our company’s ongoing development and commercial roll-out of superior products that enhance performance naturally and more quickly than industry alternatives,” said Brian Tuffin, Fuse Science’s president and chief operating officer. “Our products have the potential to provide athletes superior, performance-measurable benefits.”

Dr. Berkoff is a well-respected team physician for Duke University’s highly regarded sports programs, which include lacrosse, soccer, football and basketball. He is an expert in the treatment of sports-related injuries in collegiate and young athletes. Additionally, Dr. Berkoff works as a sports medicine consultant for the National Basketball Association (NBA). He has helped conduct pre-World Cup physicals for USA Soccer and is the former Medical Director of the Blue Devil Ironman Triathlon and the New York Triathlon Club. Dr. Berkoff has performed fitness and performance testing at the highest levels. His peer-reviewed research regarding heart rate variability of track and endurance athletes and abstracts addressing electrolyte supplementation and its impact on performance and cramping have been published in often referenced medical journals and bulletins.

Dr. Berkoff received his undergraduate degree from the University of Michigan and completed his medical training at the Albert Einstein College of Medicine at Yeshiva University in New York City. He is also a past-intern in internal medicine at Beth Israel Medical Center and resident in emergency medicine at Jacobi Medical Center. In 2003, Dr. Berkoff moved to Chapel Hill, North Carolina and subsequently completed a fellowship in primary care sports medicine at Duke University.

Dr. Berkoff’s clinical interests include non-operative orthopedics and musculoskeletal ultrasound with a focus on endurance athletes such as cyclists, runners and triathletes. He has spent time working in the Michael Krzyzewski Human Performance Lab conducting endurance-related research pertaining to cycling and bicycle fitting and previously owned and operated a private cycling performance business.

“Fuse Science’s proprietary technology could represent one of the most exciting and significant new developments for the repletion of electrolyte, vitamin and mineral deficiencies in athletes since the advent of the sports drink,” said Dr. Berkoff. “I look forward to working with the company’s Board of Directors to advance the applications for this technology.”

About Double Eagle Holdings

Double Eagle Holdings (OTCQB: DEGH.pk) is an innovative consumer products holding company and the parent company of Fuse Science, Inc. Based in Aventura, Florida, Fuse Science is the developer of patent-pending conveyance technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals, delivering benefits faster and more effectively than ever before. Information about Fuse Science is available online at www.fusescience.com or by calling 305-503-FUSE (3873).

Safe Harbor Statement: Certain statements and information included in this release may constitute “forward-looking statements” as defined in the Federal Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied in such statements. Additional discussion of factors that could cause actual results to differ materially from management’s projections, estimates and expectations is contained in the company’s SEC filings. The company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by federal securities laws.

SOURCE Fuse Science, Inc.


Source: newswire